Perisurgical management of patients with neuromuscular disorders

Neurologic Clinics

Volumn 22, Issue 2, 2004, Pages 293-313

  Bertorini, Tulio E ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIRHEUMATIC AGENT; CARDIOVASCULAR AGENT; CHOLINESTERASE INHIBITOR; CLINDAMYCIN; COLISTIN; CORTICOSTEROID; CORTICOTROPIN; DIURETIC AGENT; ERYTHROMYCIN; ESTROGEN; FLUMAZENIL; GENTAMICIN; GLUCOSE; HORMONE; KANAMYCIN; LINCOMYCIN; MAGNESIUM; MUSCLE RELAXANT AGENT; NARCOTIC AGENT; NEOMYCIN; POLYMYXIN B; QUININE; SEDATIVE AGENT; STREPTOMYCIN; TETRACYCLINE; THYROID HORMONE; TOBRAMYCIN; UNINDEXED DRUG;

AMYOTROPHIC LATERAL SCLEROSIS; APNEA; AUTOSOMAL DOMINANT DISORDER; CARDIOVASCULAR DISEASE; DISEASE EXACERBATION; DISEASE PREDISPOSITION; DRUG SENSITIVITY; EXTUBATION; FRIEDREICH ATAXIA; GASTROTOMY; HEREDITARY MOTOR SENSORY NEUROPATHY; HUMAN; LARYNGECTOMY; MALIGNANT HYPERTHERMIA; MOTOR NEURON DISEASE; MUSCLE WEAKNESS; MUSCULAR DYSTROPHY; MYASTHENIA GRAVIS; MYOTONIA; MYOTONIC DYSTROPHY; NEUROMUSCULAR DISEASE; PATIENT COUNSELING; PATIENT MONITORING; PERCUTANEOUS ENDOSCOPIC GASTROSTOMY; PERIODIC PARALYSIS; PERIOPERATIVE PERIOD; PERIPHERAL NEUROPATHY; PHYSIOTHERAPY; PLASMAPHERESIS; POSTOPERATIVE PERIOD; POTASSIUM AGGRAVATED MYOTONIA; PRIORITY JOURNAL; PROPHYLAXIS; RESPIRATORY FAILURE; REVIEW; RISK; SEDATION; SPINAL MUSCULAR ATROPHY; SURGICAL PATIENT; THOMSEN DISEASE; THYMECTOMY; TRACHEOSTOMY;

HUMANS; INTRAOPERATIVE CARE; NEUROMUSCULAR DISEASES; POSTOPERATIVE CARE; PREOPERATIVE CARE;

EID: 1642353421     PISSN: 07338619     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ncl.2004.01.003     Document Type: Review

References (109)

1. Mazzini L., Corra T., Zaccala M., Mora G., Del Piano M., Galante M. Percutaneous endoscopic gastrostomy and enteral nutrition in amyotrophic lateral sclerosis. J Neurol. 242:1995;695-698.
2. Kasarskis E.J., Neville H.E. Management of ALS: nutritional care. Neurology. 47:(Suppl 2):1996;S118-S120.
3. Albert S.M., Murphy P.L., Del Bene M.L., Rowland L.P. A prospective study of palliative care in ALS: choice, timing, outcomes. J Neurol Sci. 169:1999;108-113.
4. Miller R.G., Rosenberg J.A., Gelinas D.F., Mitsumoto H., Newman D., Sufit R., et al. Practice parameter: the care of the patient with amyotrophic lateral sclerosis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. ALS Practice Parameters Task Force. Muscle Nerve. 22:1999;1104-1118.
5. Strong M.J., Rowe A., Rankin R.N. Percutaneous gastrojejunostomy in amyotrophic lateral sclerosis. J Neurol Sci. 169:1999;128-132.
6. Hawthorne M., Gray E., Cottam C. Conservative laryngectomy: an effective treatment for severe aspiration in motor neuron disease. J Laryngol Otol. 101:1987;283-285.
7. Carter G.T., Johnson E.R., Bonekat H.W., Lieberman J.S. Laryngeal diversion in the treatment of intractable aspiration in motor neuron disease. Arch Phys Med Rehabil. 73:1992;680-682.
8. Russman B.S. Spinal muscular atrophies. Katirji B., Kaminski H.J., Preston D.C., Ruff R.L., Shaprio B.E. Neuromuscular disorders in clinical practice. 2002;445-453 Butterworth Heinemann, Boston.
9. Samaha F.J., Buncher C.R., White M.L., Innaccone S.T., Barker L., Burhans K., et al. Pulmonary function in spinal muscular atrophy. J Child Neurol. 9:1994;326-329.
10. Lyager S., Steffensen B., Juhl B. Indications of need for mechanical ventilation in Duchenne muscular dystrophy and spinal muscular atrophy. Chest. 108:1995;779-785.
11. Schwetker E.P., Gibson D.A. The orthopaedic aspects of spinal muscular atrophy. J Bone Joint Surg. 58:1976;32-38.
12. Warner W.C. Neuromuscular disorders. Canale S.T. Campbell's operative orthopaedics. 2003;1363-1383 Mosby, St. Louis.
13. Hensinger R.N., MacEwen G.D. Spinal deformity associated with heritable neurologic conditions: spinal muscular atrophy, Friedreich's ataxia, familial dysautonomia and Charcot-Marie-Tooth disease. J Bone Joint Surg Am. 58:1976;13-24.
14. Aprin H., Bowen J.R., MacEwen G.D., Hall J.E. Spine fusion in patients with spinal muscular atrophy. J Bone Joint Surg. 64:1982;1179-1187.
15. Daher Y.H., Lonstein J.E., Winter R.B., Bradford D.S. Spinal surgery in spinal muscular atrophy. J Pediatr Orthop. 5:1985;391-395.
16. Evans G.A., Drennan J.C., Russman B.S. Functional classification and orthopaedic management of spinal muscular atrophy. J Bone Joint Surg. 63B:1981;516-522.
17. Merlini L., Granata C., Bonfiglioli S., Marini M.L., Cervellati S., Savini R. Scoliosis in spinal muscular atrophy: natural history and management. Dev Med Child Neurol. 31:1989;501-508.
18. Phillips D.P., Roye D.P. Jr., Farcy J.P., Leet A., Shelton Y.A. Surgical treatment of scoliosis in a spinal muscular atrophy population. Spine. 15:1990;942-945.
19. Piasecki J.O., Mahinpour S., Levine D.B. Long-term follow up of spinal fusion in spinal muscular atrophy. Clin Orthop. Jun:(207):1986;44-54.
20. Labelle H., Tohme S., Duhaime M., Allard P. Natural history of scoliosis in Friedreich's ataxia. J Bone Joint Surg. 68:1986;564-572.
21. Alexander I.J., Johnson K.A. Assessment and management of pes cavus in Charcot-Marie-Tooth disease. Clin Orthop. Sep:(246):1989;273-281.
22. Gould N. Surgery in advanced Charcot-Marie-Tooth disease. Foot Ankle. 4:1984;267-273.
23. Miller G.M., Hsu J.D., Hoffer M.M., Rentfro R. Posterior tibial tendon transfer: a review of the literature and analysis of 74 procedures. J Pediatr Orthop. 2:1982;363-370.
24. Paulos L., Coleman S.S., Samuelson K.M. Pes cavovarus: review of a surgical approach using selective soft-tissue procedures. J Bone Joint Surg. 62:1980;942-953.
25. Seybold M.E. Treatment of myasthenia gravis. Engel A.G. Myasthenia gravis and myasthenic disorder. 1999;167-201 Oxford University Press, Oxford (UK).
26. Kaminski H.J., Fenstermaker R.A., Abdul-Karmin F.W., Clayman J., Ruff R.L. Acetylcholine receptor subunit gene expression in thymic tissue. Muscle Nerve. 16:1993;1332-1337.
27. Schluep M., Willcox N., Vincent A., Dhoot G.K., Newsom-Davis J. Acetylcholine receptors in human thymic myoid cells in situ: an immunohistological study. Ann Neurol. 22:1987;212-222.
28. Fujii Y., Hasimoto J., Monden Y., Ito T., Nakahara K., Kawashima Y. Specific activation of lymphocytes against acetylcholine receptor in the thymus in myasthenia gravis. J Immunol. 136:1986;887-891.
29. Scadding G.K., Vincent A., Newsom-Davis J., Henry K. Acetylcholine receptor antibody synthesis by thymic lymphocytes: correlation with thymic histology. Neurology. 31:1981;935-943.
30. Vincent A., Scadding G.K., Thomas H.C., Newsom-Davis J. In-vitro synthesis of antiacetylcholine receptor antibody by thymic lymphocytes in myasthenia gravis. Lancet. 1:1978;305-307.
31. Melms A., Chrestel S., Schalke B.C.G., Wekerle H., Mauron A., Ballivet M., et al. Autoimmune T lymphocytes in myasthenia gravis: determination of target epitopes using T lines and recombinant products of the mouse nicotinic acetylcholine receptor gene. J Clin Invest. 83:1989;785-790.
32. Eaton L.M., Claggett O.T. Present status of thymectomy in treatment of myasthenia gravis. Am J Med. 19:1955;703-717.
33. Oosterhius H.J. Observations of the natural history of myasthenia gravis and the effect on thymectomy. Ann N Y Acad Sci. 377:1981;678-690.
34. Simpson J.A. An evaluation of thymectomy in myasthenia gravis. Brain. 81:1958;112-144.
35. Castleman B. The pathology of the thymus gland in myasthenia gravis. Ann N Y Acad Sci. 135:1966;496-505.
36. Buckingham J.M., Howard F.M., Bernatz P.E., Payne W.A.S., Harrison E.G., O'Brien P.C., et al. The value of thymectomy in myasthenia gravis: a computer-assisted matched study. Ann Surg. 184:1976;453-458.
37. Schumm M., Weitholter H., Fatch-Moghadam A., Dichgans J. Thymectomy in myasthenia with pure ocular symptoms. J Neurol Neurosurg Psychiatry. 48:1985;332-337.
38. Seybold M., Howard F.M. Jr., Duane D.D., Payne W.A.S., Harrison E.G. Jr. Thymectomy in juvenile myasthenia gravis. Arch Neurol. 25:1971;385-392.
39. Sghirlanzoni A., Peluchietti D., Mantegazza R., Fiacchino F., Cornelio F. Myasthenia gravis: prolonged treatment with steroids. Neurology. 34:1984;170-174.
40. Olanow C.W., Wechsler A.S., Sirotkin-Roses M., Stajich J., Roses A.D. Thymectomy as primary therapy in myasthenia gravis. Ann N Y Acad Sci. 505:1987;595-606.
41. Olanow C.W., Wechsler A.S., Roses A.D. A prospective study of thymectomy and serum acetylcholine receptor antibodies in myasthenia gravis. Ann Surg. 196:1982;113-121.
42. Jaretzki A. III, Penn A.S., Younger D.S., Wolff M., Olarte M.R., Lovelace R.E., et al. "Maximal" thymectomy for myasthenia gravis. Results. J Thorac Cardiovasc Surg. 95:1988;747-757.
43. Sanders D.B., El-Salem K., Massey J.M., McConville J., Vincent A. Clinical aspects of MuSK antibody positive seronegative MG. Neurology. 60:2003;1978-1980.
44. Seybold M.E. Thymectomy in childhood myasthenia gravis. Ann N Y Acad Sci. 841:1998;731-741.
45. Faulkner S.L., Ehyai A., Fisher R.D., Fenichel G.M., Bender H.W. Jr. Contemporary management of myasthenia gravis: the clinical role of thymectomy. Ann Thorac Surg. 23:1977;348-352.
46. Sarnat H.B., McGarry J.D., Lewis J.E. Jr. Effective treatment of infantile myasthenia gravis by combined prednisone and thymectomy. Neurology. 27:1977;550-553.
47. Brearly S., Gentle T.A., Baynham M.I.D., Roberts K.D., Abrams L.D., Thompson R.A. Immunodeficiency following neonatal thymectomy in man. Clin Exp Immunol. 70:1987;322-327.
48. Mendall J.R., Warmolts J.R., Bass J.C. Caution urged in childhood thymectomy for myasthenia gravis. Neurology. 27:1977;1182.
49. Miller R.G., Filler-Katz A., Kiprov D., Roan R. Repeat thymectomy in chronic refractory myasthenia gravis. Neurology. 41:1991;923-924.
50. Mulder G.C., Graves M., Herrmann C. Thymectomy for myasthenia gravis: recent observations and comparisons with past experience. Ann Thorac Surg. 48:1989;551-555.
51. Klingen G., Johansson L., Westerholm C.-J., Sundstrom C. Transcervical thymectomy with the aid of mediastinoscopy for myasthenia gravis: eight years experience. Ann Thorac Surg. 23:1977;342-347.
52. Cooper J.D., Al-Jalaihawa A.N., Pearson F.G., Humphrey J.G., Humphrey H.E. An improved technique to facilitate transcervical thymectomy for myasthenia gravis. Ann Thorac Surg. 45:1988;242-247.
53. Jaretzki A. III, Penn A.S., Younger D.S., Wolff M., Olarte M.R., Lovelace R.E., et al. "Maximal" thymectomy for myasthenia gravis results. J Thorac Cardiovasc Surg. 96:1988;711-716.
54. Masaoka A., Monden Y. Comparison of the results of transsternal simple, transcervical simple, and extended thymectomy. Ann N Y Acad Sci. 377:1981;755-765.
55. Drachman D.B. Myasthenia gravis. N Engl J Med. 330:1994;1797-1810.
56. Machens A., Emskotten T., Busch C., Izbides J.R. Postoperative infection after transsternal thymectomy, a retrospective analysis of 125 cases. Surg Today. 28:1998;808-810.
57. d'Empaire G., Hoalin D.C., Perlo V.P., Pontoppidan H. Effect of prethymectomy plasma exchange on postoperative respiratory function in myasthenia gravis. J Thorac Cardiovasc Surg. 89:1985;592-596.
58. Spence P.A., Morin J.E., Katz M. Role of plasmapheresis in preparing myasthenic patients for thymectomy: initial results. Can J Surg. 27:1984;303-305.
59. Kas J., Kiss D., Simon V., Svastics E., Major L., Szobor A. Decade-long experience with surgical therapy of myasthenia gravis; early complications of 324 transsternal thymectomies. Ann Thorac Surg. 72:2001;1691-1697.
60. Roy L., Gibson D. Pseudohypertrophic muscular dystrophy and its surgical management: review of 30 patients. Can J Surg. 13:1970;13-21.
61. Spencer G.E. Jr. Orthopaedic care of progressive muscular dystrophy. J Bone Joint Surg Am. 49:1967;1201-1204.
62. Rideau Y., Duport G., Delaubier A., Guillou C., Renardel-Irani A., Bach J.R. Early treatment to preserve quality of locomotion for children with Duchenne's muscular dystrophy. Semin Neurol. 15:1995;9-17.
63. Granata C., Giannini S., Ballestrazzi L., Merlini L. Early surgery in Duchenne muscular dystrophy: experience at Istituto Ortopedico Rizzoli, Bologna. Italy. Neuromuscular Disord. 4:1994;87-88.
64. Miller R.G., Chalmers A.C., Dao H., Filler-Katz A., Holman D., Bost F. The effect of spine fusion on respiratory function in Duchenne muscular dystrophy. Neurology. 41:1991;38-40.
65. Brook P.D., Kennedy J.D., Stern L.M., Sutherland A.D., Foster B.K. Spinal fusion in Duchenne's muscular dystrophy. J Pediatr Orthop. 16:1996;324-331.
66. Seeger B.R., Sutherland A.D., Clark M.S. Orthotic management of scoliosis in Duchenne muscular dystrophy. Arch Phys Med Rehabil. 65:1984;83-86.
67. Shapiro F., Sethna N., Colan S., Wohl M.E., Specht L. Spinal fusion in Duchenne muscular dystrophy: a multidisciplinary approach. Muscle Nerve. 15:1992;604-614.
68. Cambridge W., Drennan J.C. Scoliosis associated with Duchenne muscular dystrophy. J Pediatr Orthop. 7:1987;436-440.
69. Shapiro F., Specht L. Orthopedic deformities in Emery-Dreifuss muscular dystrophy. J Pediatr Orthop. 11:1991;336-340.
70. Finsterer J., Bittner R.E., Grimm M. Cardiac involvement in Becker's muscular dystrophy necessitating heart transplantation, 6 years before apparent muscle involvement. Neuromuscular Disord. 9:1999;598-600.
71. Jakab E., Gledhill R.B. Simplified technique for scapulocostal fusion in the fascioscapulohumeral dystrophy. J Pediatr Orthop. 13:1993;749-751.
72. Bertorini T.E. Myoglobinuria, malignant hyperthermia, neuroleptic malignant syndrome and serotonin syndrome. Neurol Clin. 15:1997;649-671.
73. Harper PS, Rudel R. Myotonic dystrophy. In: Engel AG, Franzini-Armstrong C, editors. New York: McGraw-Hill Inc. Myopathy, volume 2. p. 1192-219.
74. Mathieu J., Allard P., Gobeil G., Girard M., DeBraekeleer M. Anesthetic and surgical complications in 219 cases of myotonic dystrophy. Neurology. 49:1997;1646-1650.
75. Dundee J. Thiopentone in dystrophia myotonica. Anesth Analg. 31:1951;256-260.
76. Aldridge L.M. Anaesthetic problems in myotonic dystrophy: a case report and review of the Aberdeen experience compromising 48 general anesthetics in a further 16 patients. Br J Anaesth. 57:1985;1119-1130.
77. Thiel R.E. The myotonic response to suxamethonium. Br J Anasthes. 39:1967;815-820.
78. Russell S.H.E., Hirsch N.P. Anaesthesia and myotonia. Br J Anaesth. 72:1994;210-216.
79. Pederson T., Eliasen K., Henriksen E. A prospective study of risk factors and cardiopulmonary complications associated with anesthesia and surgery: risk indications of cardiopulmonary morbidity. Acta Anaesthesiol Scand. 34:1990;144-155.
80. Kilburn K.H., Eagon J.T., Sieker H.O., Heyman A. Cardiopulmonary insufficiency in myotonic and progressive muscular dystrophy. N Engl J Med. 262:1959;1089-1096.
81. Mathieu J., Allard P., Gobeil G., Girard M., De Braekeleer M., Begin P. Anesthetic and surgical complications in 219 cases of myotonic dystrophy. Neurol. 49:1997;1646-1650.
82. Imison A.R. Anesthesia and myotonia: an Australian experience. Anaesth Intensive Care. 29:2001;34-37.
83. Mosley R.T. III. Myotonic muscular dystrophy. Rowland L.P., DiMauro S. Handbook of clinical neurology: myopathies. 2nd edition:1992;209-259 Elsevier Science, Amsterdam.
84. Harper P.S. Myotonic dystrophy. 2nd edition:1989;WB Saunders, London.
85. Hudson A.J., Ebers G.C., Bulman D.E. The skeletal muscle sodium and chloride channel disease. Brain. 118:1995;547-563.
86. Russell S.H.E., Hirsch N.P. Anaesthesia and myotonia. Br J Anaesth. 72:1994;210-216.
87. Vita G.M., Olckers A., Jedicka A.E., George A.L., Heiman-Patterson T., Rosenberg H., et al. Masseter muscle rigidity associated with glycine 1306-to-alanine mutation in the adult muscle sodium channel alpha-subunit gene. Anesthesiology. 82:1995;1097-1103.
88. England D.E. Mutant sodium channels, myotonia and propofol. Muscle Nerve. 24:2001;713-715.
89. Haeseler G., Stormer M., Mohammadi B., Bufler J., Dengler R., Piepenbrock S., et al. The anesthetic propofol modulates gating in paramyotonia congenita-mutant muscle sodium channels. Muscle Nerve. 24:2001;736-743.
90. Denborough M.A., Lovell R.R.H. Anaesthetic deaths in a family. Lancet. 2:1960;45.
91. Jurkat-Rott K., McCarthy T., Lehmann-Horn E. Genetics and pathogenesis of malignant hyperthermia. Muscle Nerve. 23:2000;4-17.
92. Bertorini T. Malignant hyperthermia. Kaminski H.J. Neuromuscular disorders in clinical practice. 2002;1021-1027 Butterworth-Heinemann, Boston.
93. Gronert G.A. Malignant hyperthermia. Engel A.G., Franzini-Armstrong C. Myology. volume 2:1994;1661-1678 McGraw-Hill, New York.
94. Quane K.A., Healy J.M., Keating K.E., Manning B.M., Couch F.J., Palmucci L.M., et al. Mutations in the ryanodine receptor gene in central core disease and malignant hyperthermia. Nat Gent. 5:1993;51-55.
95. Manning B.M., Quane K.A., Ording H., Urwyler A., Tegazzin V., Lehane M., et al. Identification of novel mutations in the ryanodine receptor gene (ryanodine-receptor 1) in malignant hyperthermia: genotype phenotype. Am J Hum Genet. 62:1998;599-609.
96. Iles D.E., Lehmann-Horn F., Scherer S.W., Tsui L.C., Olde Weghuis D., Suijkerbuijk R.F., et al. Localization of the gene encoding the alpha 2/delta- subunits of the L-type voltage-dependent calcium channel to chromosome 7q and analysis of the segregation of flanking markers in malignant hyperthermia susceptible families. Hum Mol Genet. 3:1994;969-975.
97. Monnier N., Procaccio V., Stieglitz P., Lunardi J. Malignant hyperthermia susceptibility is associated with a mutation of the ac-1-subunit of the human DHP-sensitive L-type voltage-dependent calcium-channel receptor in skeletal muscle. Am J Hum Genet. 60:1997;1316-1325.
98. Nelson T.E., Flewellen E.H. Current concepts: the malignant hyperthermia syndrome. N Engl J Med. 309:1983;416-418.
99. Finsteres J. Current concepts in malignant hyperthermia. Journal of Clinical Neuromuscular Disease. 4:2002;64-74.
100. Nelson T.E., Sweo T. Ca2+ uptake and Ca2+ release by skeletal muscle sarcoplasmic reticulum; differing sensitivity to inhalational anesthetics. Anesthesiology. 69:1988;571-577.
101. el Hayek R., Yano M., Antoniu B., Mickelson J.R., Louis C.F., Ikemoto N. Altered E-C coupling in triads isolated from malignant hyperthermia-susceptible porcine muscle. Am J Physiol. 268:1995;C1381-C1386.
102. MacLennan D.H., Phillips M.S. Malignant hyperthermia. Science. 256:1992;789-794.
103. McCarthy T.V., Healy J.M., Heffron J.J., Lehane M., Deufel T., Lehmann-Horn F., et al. Localization of the malignant hyperthermia susceptibility locus to human chromosome 19q12-13.2. Nature. 343:1990;562-563.
104. Loke J., MacLennan D.H. Malignant hyperthermia and central core disease: disorders of Ca2+ release channels. Am J Med. 104:1998;470-486.
105. Heiman-Patterson T.D., Rosenberg H., Fletcher J.E., Tahmoush A.J. Halothane-caffeine contracture testing in neuromuscular disease. Muscle Nerve. 11:1988;453-457.
106. A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility. The European Malignant Hyperpyrexia Group. Br J Anaesth. 56:1984;1267-1269.
107. Larach M.G. Standardization of the caffeine halothane muscle contracture test. North American Malignant Hyperthermia Group. Anesth Analg. 69:1989;511-515.
108. Fletcher J.E., Rosenberg H., Aggarwal M. Comparison of European and North American malignant hyperthermia diagnostic protocol outcomes for use in genetic studies. Anesthesiology. 90:1999;654-661.
109. Malignant Hyperthermia Association of the United States (MHAUS). Emergency therapy for malignant hyperthermia. 1995;Malignant Hyperthermia Association of the United States, New York.